Some People Run from Challenges.
We Run to Them.
It takes a special kind of person to confront
challenges that seem insurmountable.
It takes grit, confidence and smarts.
Yasutoshi Kawakami became President of TPA (previously Mitsubishi Tanabe Pharma America) in 2023 after decades with the Tanabe Pharma Corporation group and will lead TPA into the future by harnessing a rich, 300-year history and modern science-driven mindset to further establish TPA as a key player in the U.S. pharmaceutical field.
Part of enfolding the health of people around the world is identifying with them on a personal level. At TPA, culture & belonging are integral components of our formula for innovation. The distinct experiences, backgrounds, and perspectives that each member of our team brings act as the catalyst for groundbreaking ideas and, subsequently, create hope for those who must face illnesses head-on. By fostering a culture of belonging we enhance problem-solving, expand our customer base, and address unmet needs more effectively. Cultivating a sense of belonging isn’t just beneficial for our bottom line—it’s better for humanity.
Registration of Clinical Trial Information and Disclosure of Results
a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries
TPA will register and disclose information on publicly accessible clinical trial registries such as ClinicalTrials.gov regarding clinical trials that are being conducted or have been conducted.
b. Disclosure of clinical trial summary results
TPA will disclose the results from clinical trials in patients that form part of the submission package for products approved in the United States. Results will not be disclosed if TPA decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:
- A third party, such as a company involved in joint development, has not agreed to disclosure.
- Disclosure may interfere with publication in medical journals.
- Disclosure may interfere with the protection of intellectual property rights.